Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Ana Arencibia, Moises Diago, Javier García-Samaniego, Jose Castellote, Susana Llerena, Elisa Rodríguez-Seguel, Beatriz Mateos, Manuel Rodríguez, Jose Miguel Rosales Zabal, Inmaculada Fernández, Jose Luis Calleja, Rosa María Morillas, Silvia Montoliu, Raul J Andrade, Ester Badia Aranda, Manuel Hernández-Guerra, Carlota Jimeno Maté, Jesús M González-Santiago, Beatriz de Cuenca, Vanesa Bernal-Monterde, Manuel Delgado, Juan Turnes, Sabela Lens, María Buti
BACKGROUND: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). METHODS: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022...
May 2, 2024: Alimentary Pharmacology & Therapeutics